Cepheid, a Danaher company and a leader in molecular diagnostics for infectious diseases, and Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology for real-time genomic analysis, announced an expansion of their partnership to develop a workflow for rapid bacterial and fungal pathogen identification. Following a successful phase one collaboration announced at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2025, the companies are advancing to the next phase of development, building on a promising beta solution already in use by researchers. In this next phase, the updated workflow will enable pathogen identification, antimicrobial resistance profiling, and genomic antibiotic susceptibility testing predictions for bloodstream infection and sepsis research.
These analyses will be performed using both culture isolates and positive blood cultures. This phase will include additional user-friendly product design elements and expanded access through a co-commercialized research use only (RUO) launch. The initial workflow, designed to profile bacterial and fungal pathogens from culture isolates for sepsis and bloodstream infection research, has shown promise.
Multiple infectious disease researchers already have early beta access, and by Third Quarter 2026, the workflow will be available through an early access program to several leading physician-scientists. Cepheid and Oxford Nanopore share a long-term ambition to deliver an end-to-end in vitro diagnostic (IVD) solution for complex infectious diseases, with the goal of enabling more accurate and timely clinical decisions. They will be present at ESCMID Global this week, showcasing research-stage progress and engaging with the scientific community.
For Research Use Only. Not for use in diagnostic procedures.
